The external validity of randomized controlled trials of hypertension within China: from the perspective of sample representation.

<h4>Objective</h4>To explore external validity of randomized controlled trials (RCTs) of hypertension within China from the view of sample representation.<h4>Methods</h4>Comprehensive literature searches were performed in Medline, Embase, Cochrane Central Register of Controll...

Full description

Bibliographic Details
Main Authors: Xin Zhang, Yuxia Wu, Deying Kang, Jialiang Wang, Qi Hong, Le Peng
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24324771/?tool=EBI
id doaj-6d176f9497254fa1a26289445d101ead
record_format Article
spelling doaj-6d176f9497254fa1a26289445d101ead2021-03-04T10:10:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01812e8232410.1371/journal.pone.0082324The external validity of randomized controlled trials of hypertension within China: from the perspective of sample representation.Xin ZhangYuxia WuDeying KangJialiang WangQi HongLe Peng<h4>Objective</h4>To explore external validity of randomized controlled trials (RCTs) of hypertension within China from the view of sample representation.<h4>Methods</h4>Comprehensive literature searches were performed in Medline, Embase, Cochrane Central Register of Controlled Trials (CCTR) et al and advanced search strategies were used to locate hypertension RCTs as well as observational studies conducted in China during 1996 to 2009 synchronously. The risk of bias in RCTs and observational studies was assessed by two modified scales respectively, and then both types of studies with 3 or more grading scores were included for the purpose of evaluating of external validity. Following that the study characteristics relative to sample representation were extracted from RCTs and observational studies synchronously, and the later were taken as external references for validating sample representation of RCTs.<h4>Results</h4>226 hypertension RCTs and 21 observational studies were included for final analysis. Comparing samples with observational studies, the mean age of samples within RCTs was 54.46 years, significantly lower than that of observational studies (66.35 years) (P=0.002). The average disease course in patients of RCTs was 3.89 years and grade III hypertensive patients accounted for 17%; both were lower than that of the observational studies (12.96 years, P<0.001; 34%, P=0.026 respectively). In addition, the proportions of patients with complications due to heart failure, stroke, diabetes, or coronary heart disease in RCTs were 8%, 5%, 12% and 11% correspondingly, all of which were significantly less than that of observational studies (11%, 18%, 17% and 29%).<h4>Conclusion</h4>Sample characteristics within hypertension RCTs were significantly different from those in observational studies. The samples in most RCTs were under-represented. It's feasible to take samples of observational studies as a mirror of the actual composition of hypertension patients in the real world, if the reporting of observational studies is abundant and available.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24324771/?tool=EBI
collection DOAJ
language English
format Article
sources DOAJ
author Xin Zhang
Yuxia Wu
Deying Kang
Jialiang Wang
Qi Hong
Le Peng
spellingShingle Xin Zhang
Yuxia Wu
Deying Kang
Jialiang Wang
Qi Hong
Le Peng
The external validity of randomized controlled trials of hypertension within China: from the perspective of sample representation.
PLoS ONE
author_facet Xin Zhang
Yuxia Wu
Deying Kang
Jialiang Wang
Qi Hong
Le Peng
author_sort Xin Zhang
title The external validity of randomized controlled trials of hypertension within China: from the perspective of sample representation.
title_short The external validity of randomized controlled trials of hypertension within China: from the perspective of sample representation.
title_full The external validity of randomized controlled trials of hypertension within China: from the perspective of sample representation.
title_fullStr The external validity of randomized controlled trials of hypertension within China: from the perspective of sample representation.
title_full_unstemmed The external validity of randomized controlled trials of hypertension within China: from the perspective of sample representation.
title_sort external validity of randomized controlled trials of hypertension within china: from the perspective of sample representation.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description <h4>Objective</h4>To explore external validity of randomized controlled trials (RCTs) of hypertension within China from the view of sample representation.<h4>Methods</h4>Comprehensive literature searches were performed in Medline, Embase, Cochrane Central Register of Controlled Trials (CCTR) et al and advanced search strategies were used to locate hypertension RCTs as well as observational studies conducted in China during 1996 to 2009 synchronously. The risk of bias in RCTs and observational studies was assessed by two modified scales respectively, and then both types of studies with 3 or more grading scores were included for the purpose of evaluating of external validity. Following that the study characteristics relative to sample representation were extracted from RCTs and observational studies synchronously, and the later were taken as external references for validating sample representation of RCTs.<h4>Results</h4>226 hypertension RCTs and 21 observational studies were included for final analysis. Comparing samples with observational studies, the mean age of samples within RCTs was 54.46 years, significantly lower than that of observational studies (66.35 years) (P=0.002). The average disease course in patients of RCTs was 3.89 years and grade III hypertensive patients accounted for 17%; both were lower than that of the observational studies (12.96 years, P<0.001; 34%, P=0.026 respectively). In addition, the proportions of patients with complications due to heart failure, stroke, diabetes, or coronary heart disease in RCTs were 8%, 5%, 12% and 11% correspondingly, all of which were significantly less than that of observational studies (11%, 18%, 17% and 29%).<h4>Conclusion</h4>Sample characteristics within hypertension RCTs were significantly different from those in observational studies. The samples in most RCTs were under-represented. It's feasible to take samples of observational studies as a mirror of the actual composition of hypertension patients in the real world, if the reporting of observational studies is abundant and available.
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24324771/?tool=EBI
work_keys_str_mv AT xinzhang theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT yuxiawu theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT deyingkang theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT jialiangwang theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT qihong theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT lepeng theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT xinzhang externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT yuxiawu externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT deyingkang externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT jialiangwang externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT qihong externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT lepeng externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
_version_ 1714806584734908416